Advaxis to present at the summit for drug development for non-small cell lung cancer

Watch Free Movies and TV shows Apps

🎬📺 Free Movies and Free TV Shows! 🎭🎬


img

PRINCETON, NJ, July 14, 2021 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS)), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, MD, Advaxis Executive Vice President and Chief Medical Officer, will present data from Part B of the Phase 1/2 Company’s study of ADXS-503 in combination with pembrolizumab in patients with metastatic squamous or non-squamous cell non-small cell lung cancer at the Virtual Non-Small Cell Lung Cancer Drug Development Summit on July 15this, 2021.

Presentation title: Can neoantigen immunotherapies reverse PD-1 inhibitor resistance and progression in NSCLC?
Session Title: Immunotherapy Strategy for NSCLC
Session type: Virtual presentation
Date and time: 7/15-2021, 9:30 AM (ETT)

Watch Free Movies and TV shows Apps

🎬📺 Free Movies and Free TV Shows! 🎭🎬

About Advaxis, Inc.
Advaxis, Inc. is a clinical stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that uses live attenuated Listeria monocytogenes (Lm), bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are considered an important advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen-presenting cells to stimulate anti-tumor T-cell immunity, boost the immune system with the equivalent of multiple adjuvants, while reducing tumor protection in the tumor microenvironment to allow T cells to eliminate tumors.

For more information about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements
This press release contains forward-looking statements made in accordance with the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements that express management’s current beliefs and expectations, including, but not limited to, statements regarding the anticipated clinical development of the Company’s drug candidates, statements about the Company’s cash and cash equivalents to fund its future obligations, and statements regarding the company’s goals, plans and expectations for its ongoing clinical trials. These and other risks are discussed in the Company’s filings with the SEC, including, but not limited to, the Annual Report on Form 10-K, filed Jan. 22, 2021, and the Periodic Reports on Form 10-Q and Form 8-K. Any statements contained herein that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and performance to differ materially from those discussed in such forward-looking statements. The company cautions readers not to place undue reliance on forward-looking statements, which speak only as of the date they are made. The company assumes no obligation to update or revise any forward-looking statements, unless otherwise required by law, whether as a result of new information, future events or otherwise.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Contact for investors
Tim McCarthy
LifeSci Advisors, LLC
Tim@lifesciaadvisors.com
(212) 915-2564

Watch Free Movies and TV shows Apps

🎬📺 Free Movies and Free TV Shows! 🎭🎬

[ Sharing is Caring! ] Tags: ARE CANCER CLINICAL TRIALS SAFE, LUNG CANCER
This div height required for enabling the sticky sidebar